Corbus Pharmaceuticals Holdings, Inc. Interest Income (Expense), Net
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Interest Income (Expense), Net of $1.19 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2024-11-07
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for the quarter ending 2024-09-30 was $1.19M, a 447.93% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for the quarter ending 2024-06-30 was $906.00K, a 290.52% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for the quarter ending 2024-03-31 was -$177.01K.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for the quarter ending 2023-12-31 was -$3.63M.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for fiscal 2023 was -$2.92M.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for fiscal 2022 was -$2.13M.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for fiscal 2021 was -$1.83M.
- Corbus Pharmaceuticals Holdings, Inc. interest income (expense), net for fiscal 2020 was -$1.03M, a 183.77% decline from fiscal 2019.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 3 month as first filed | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 6 month as first filed | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 9 month as first filed | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $1.19M 10-Q · filed 2024-11-07 | $2.10M derived: sum of 2 quarters · filed 2024-11-07 | $2.76M 10-Q · filed 2024-11-07 | -$1.72M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2024-06-30 | $906.00K 10-Q · filed 2024-08-06 | $1.57M 10-Q · filed 2024-08-06 | -$2.91M derived: sum of 3 quarters · filed 2024-08-06 | -$2.69M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2024-03-31 | -$177.01K 10-Q · filed 2024-05-07 | -$3.81M derived: sum of 2 quarters · filed 2024-05-07 | -$3.59M derived: sum of 3 quarters · filed 2024-11-07 | -$3.36M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$3.42M derived: sum of 2 quarters · filed 2024-11-07 | -$3.19M derived: sum of 3 quarters · filed 2024-11-07 | -$2.92M 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $217.00K 10-Q · filed 2024-11-07 | -$763.36K 10-Q · filed 2023-11-07 | $449.00K derived: sum of 2 quarters · filed 2024-11-07 | $711.00K 10-Q · filed 2024-11-07 | -$2.22M 10-Q · filed 2023-11-07 | -$869.98K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $232.00K 10-Q · filed 2024-08-06 | -$775.59K 10-Q · filed 2023-08-08 | $494.00K 10-Q · filed 2024-08-06 | -$1.45M 10-Q · filed 2023-08-08 | -$1.09M derived: sum of 3 quarters · filed 2024-08-06 | -$1.63M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$678.02K 10-Q · filed 2024-05-07 | -$1.32M derived: sum of 2 quarters · filed 2024-05-07 | -$1.86M derived: sum of 3 quarters · filed 2024-05-07 | -$2.35M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | -$640.95K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$1.18M derived: sum of 2 quarters · filed 2024-03-12 | -$1.67M derived: sum of 3 quarters · filed 2024-03-12 | -$2.13M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | -$541.89K 10-Q · filed 2023-11-07 | -$1.03M derived: sum of 2 quarters · filed 2023-11-07 | -$1.49M 10-Q · filed 2023-11-07 | -$1.88M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | -$490.34K 10-Q · filed 2023-08-08 | -$949.25K 10-Q · filed 2023-08-08 | -$1.34M derived: sum of 3 quarters · filed 2023-08-08 | -$1.73M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | -$458.91K 10-Q · filed 2023-05-09 | -$849.81K derived: sum of 2 quarters · filed 2023-05-09 | -$1.24M derived: sum of 3 quarters · filed 2023-05-09 | -$1.64M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$390.90K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$782.77K derived: sum of 2 quarters · filed 2023-03-07 | -$1.18M derived: sum of 3 quarters · filed 2023-03-07 | -$1.83M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | -$391.87K 10-Q · filed 2022-11-08 | -$793.04K derived: sum of 2 quarters · filed 2022-11-08 | -$1.44M 10-Q · filed 2022-11-08 | -$2.12M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | -$401.17K 10-Q · filed 2022-08-09 | -$1.05M 10-Q · filed 2022-08-09 | -$1.73M derived: sum of 3 quarters · filed 2022-08-09 | -$2.18M derived: sum of 4 quarters · filed 2022-08-09 | |||
| 2021-03-31 | -$646.55K 10-Q · filed 2022-05-10 | -$1.33M derived: sum of 2 quarters · filed 2022-05-10 | -$1.78M derived: sum of 3 quarters · filed 2022-05-10 | -$1.77M derived: sum of 4 quarters · filed 2022-05-10 | |||
| 2020-12-31 | -$679.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$1.13M derived: sum of 2 quarters · filed 2022-03-08 | -$1.12M derived: sum of 3 quarters · filed 2022-03-08 | -$1.03M 10-K · filed 2022-03-08 | |||
| 2020-09-30 | -$454.32K 10-Q · filed 2021-11-12 | -$441.67K derived: sum of 2 quarters · filed 2021-11-12 | -$348.65K 10-Q · filed 2021-11-12 | -$188.20K derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $12.65K 10-Q · filed 2021-08-12 | $114.64K 10-Q · filed 2021-08-12 | $266.12K derived: sum of 3 quarters · filed 2021-08-12 | $558.97K derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $101.99K 10-Q · filed 2021-05-13 | $253.47K derived: sum of 2 quarters · filed 2021-05-13 | $546.32K derived: sum of 3 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $151.48K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $444.33K derived: sum of 2 quarters · filed 2021-03-15 | $1.23M 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $292.85K 10-Q · filed 2020-11-09 | $1.08M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |